• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

HBV 疫苗加 TLR9 佐剂在 HIV 初免人群中的免疫原性和安全性

Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus.

机构信息

Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, USA.

Center for Biostatistics in AIDS Research in the Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.

出版信息

Clin Infect Dis. 2023 Aug 14;77(3):414-418. doi: 10.1093/cid/ciad201.

DOI:10.1093/cid/ciad201
PMID:37017075
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10681652/
Abstract

In this international, multicenter open-label study (ACTG A5379) of HepB-CpG vaccine in people with human immunodeficiency virus (HIV) without prior hepatitis B virus (HBV) vaccination, all 68 participants achieved HBV seroprotective titers after the 3-dose series in the primary analysis. No unexpected safety issues were observed.

摘要

在这项针对未接种过乙型肝炎病毒（HBV）疫苗的人类免疫缺陷病毒（HIV）感染者的乙型肝炎核心相关抗原（HBcAg）CpG 疫苗的国际、多中心、开放性研究（ACTG A5379）中，主要分析显示，所有 68 名参与者在完成 3 剂系列疫苗接种后均达到了 HBV 血清保护性滴度。未观察到意外的安全性问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad70/10681652/cb8d72e7ef76/ciad201_ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad70/10681652/cb8d72e7ef76/ciad201_ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad70/10681652/cb8d72e7ef76/ciad201_ga1.jpg

相似文献

1
Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus.HBV 疫苗加 TLR9 佐剂在 HIV 初免人群中的免疫原性和安全性
Clin Infect Dis. 2023 Aug 14;77(3):414-418. doi: 10.1093/cid/ciad201.
2
HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse: The BEe-HIVe Randomized Clinical Trial.乙肝-CpG疫苗与乙肝-铝盐疫苗在HIV感染者及既往疫苗无应答者中的比较：BEe-HIVe随机临床试验
JAMA. 2025 Jan 28;333(4):295-306. doi: 10.1001/jama.2024.24490.
3
Posttransplant HBV Vaccine Compliance, Seroprotection, and Kinetics of Hepatitis B Surface Antibody in Thoracic Organ Transplant Recipients.胸器官移植受者的移植后乙肝疫苗依从性、血清保护及乙肝表面抗体动力学
Transpl Infect Dis. 2025 May-Jun;27(3):e70015. doi: 10.1111/tid.70015. Epub 2025 Feb 24.
4
The immunogenicity of GSK's recombinant hepatitis B vaccine in children: a systematic review of 30 years of experience.葛兰素史克重组乙型肝炎疫苗在儿童中的免疫原性：对30年经验的系统评价
Expert Rev Vaccines. 2017 Aug;16(8):789-809. doi: 10.1080/14760584.2017.1338569. Epub 2017 Jul 3.
5
Hepatitis B vaccination with HepB-CpG in people living with HIV: a narrative review.在艾滋病毒感染者中使用乙肝-卡介苗进行乙肝疫苗接种：一项叙述性综述。
Expert Rev Vaccines. 2025 Dec;24(1):365-372. doi: 10.1080/14760584.2025.2502643. Epub 2025 May 12.
6
Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: a meta-analysis?与标准剂量疫苗接种相比，增加乙肝疫苗接种剂量是否能使HIV感染患者产生更好的免疫反应：一项荟萃分析？
Int J STD AIDS. 2013 Feb;24(2):117-22. doi: 10.1177/0956462412472309. Epub 2013 May 6.
7
Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease.慢性肾脏病成人中乙型肝炎疫苗 HepB-CpG（HEPLISAV-B）与 HepB-Eng（Engerix-B）的长期免疫原性和安全性比较。
Vaccine. 2023 May 11;41(20):3224-3232. doi: 10.1016/j.vaccine.2023.04.028. Epub 2023 Apr 19.
8
An efficient vaccine clinical trial: ACTG A5379 hepatitis B vaccine trial in persons with HIV.一项高效的疫苗临床试验：美国国立过敏和传染病研究所艾滋病临床试验组A5379号针对HIV感染者的乙肝疫苗试验
Vaccine. 2025 May 10;55:127028. doi: 10.1016/j.vaccine.2025.127028. Epub 2025 Mar 26.
9
Heplisav-B: A Hepatitis B Vaccine With a Novel Adjuvant.欣毕泰：一种含新型佐剂的乙型肝炎疫苗。
Ann Pharmacother. 2021 Jun;55(6):783-791. doi: 10.1177/1060028020962050. Epub 2020 Sep 28.
10
Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.在慢性肾脏病患者中，与已上市乙型肝炎疫苗相比，含 Toll 样受体 9 激动剂佐剂（HBsAg-1018）的乙型肝炎疫苗的免疫原性和安全性。
Vaccine. 2013 Nov 4;31(46):5306-13. doi: 10.1016/j.vaccine.2013.05.067. Epub 2013 May 30.

引用本文的文献

1
Hepatitis B Boosters Using a Different Product vs. the Same Product for Kidney Transplant Recipients: A Retrospective Study With Bayesian Inference.肾移植受者使用不同产品与相同产品进行乙型肝炎疫苗加强接种：一项基于贝叶斯推理的回顾性研究
Clin Transplant. 2025 Sep;39(9):e70307. doi: 10.1111/ctr.70307.
2
Toll-like Receptor (TLR) Response in Chikungunya Virus Infection: Mechanism of Activation, Immune Evasion, and Use of TLR Agonists in Vaccine Development.基孔肯雅病毒感染中的Toll样受体（TLR）反应：激活机制、免疫逃逸以及TLR激动剂在疫苗开发中的应用
Vaccines (Basel). 2025 Aug 13;13(8):856. doi: 10.3390/vaccines13080856.
3
CROI 2025: The Challenges of Sustaining Viral Suppression, Addressing Advanced HIV Disease, and Ending the HIV Epidemic Targets.

本文引用的文献

1
Immune Response to Hepatitis B Virus Vaccine Among People Living With HIV: A Meta-Analysis.乙型肝炎病毒疫苗免疫反应在 HIV 感染者中的Meta 分析。
Front Immunol. 2021 Dec 22;12:745541. doi: 10.3389/fimmu.2021.745541. eCollection 2021.
2
Serological response with Heplisav-B® in prior Hepatitis B vaccine non-responders living with HIV.在既往对乙型肝炎疫苗无应答的 HIV 感染者中，Heplisav-B®的血清学应答。
Vaccine. 2021 Oct 22;39(44):6529-6534. doi: 10.1016/j.vaccine.2021.09.050. Epub 2021 Sep 30.
3
Brief Report: Heplisav-B Seroprotection in People With HIV: A Single-Center Experience.
2025年逆转录病毒和机会性感染会议：维持病毒抑制、应对晚期艾滋病疾病及实现艾滋病流行终结目标面临的挑战
Top Antivir Med. 2025 Jun 30;33(3):569-595.
4
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions.优化卡博特韦加rilpivirine长效疗法在HIV治疗中的应用：证据、实施及未解决的问题
Open Forum Infect Dis. 2025 Jul 3;12(7):ofaf368. doi: 10.1093/ofid/ofaf368. eCollection 2025 Jul.
5
Use of dual antiretroviral therapy in individuals with different serological patterns for hepatitis B: What are the risks? What are the clinical implications?在具有不同乙型肝炎血清学模式的个体中使用双重抗逆转录病毒疗法：风险有哪些？临床意义是什么？
HIV Med. 2025 Aug;26(8):1317-1320. doi: 10.1111/hiv.70063. Epub 2025 Jun 16.
6
Hepatitis B virus infection after immunization: How serious it is? An updated review.免疫接种后感染乙肝病毒：有多严重？最新综述。
Clin Exp Med. 2025 Apr 10;25(1):113. doi: 10.1007/s10238-025-01645-8.
7
An efficient vaccine clinical trial: ACTG A5379 hepatitis B vaccine trial in persons with HIV.一项高效的疫苗临床试验：美国国立过敏和传染病研究所艾滋病临床试验组A5379号针对HIV感染者的乙肝疫苗试验
Vaccine. 2025 May 10;55:127028. doi: 10.1016/j.vaccine.2025.127028. Epub 2025 Mar 26.
8
Update on Vaccination Recommendations for Adults with HIV.成人HIV感染者疫苗接种建议的最新情况
Curr HIV/AIDS Rep. 2025 Feb 20;22(1):17. doi: 10.1007/s11904-025-00731-6.
9
HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse: The BEe-HIVe Randomized Clinical Trial.乙肝-CpG疫苗与乙肝-铝盐疫苗在HIV感染者及既往疫苗无应答者中的比较：BEe-HIVe随机临床试验
JAMA. 2025 Jan 28;333(4):295-306. doi: 10.1001/jama.2024.24490.
10
Hepatitis B Vaccine: Four Decades on.乙肝疫苗：四十年回顾
Vaccines (Basel). 2024 Apr 18;12(4):439. doi: 10.3390/vaccines12040439.
简要报告：HIV 感染者中 Heplisav-B 的血清保护作用：单中心经验。
J Acquir Immune Defic Syndr. 2021 Apr 1;86(4):445-449. doi: 10.1097/QAI.0000000000002573.
4
Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.两种剂量的研究性乙型肝炎疫苗 HBsAg-1018 与已上市乙型肝炎疫苗在成人中的免疫原性比较：使用 Toll 样受体 9 激动剂佐剂
Vaccine. 2018 Jan 29;36(5):668-674. doi: 10.1016/j.vaccine.2017.12.038. Epub 2017 Dec 27.
5
Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.在慢性肾脏病患者中，与已上市乙型肝炎疫苗相比，含 Toll 样受体 9 激动剂佐剂（HBsAg-1018）的乙型肝炎疫苗的免疫原性和安全性。
Vaccine. 2013 Nov 4;31(46):5306-13. doi: 10.1016/j.vaccine.2013.05.067. Epub 2013 May 30.
6
Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.在 40-70 岁健康成年人中，与已上市乙型肝炎疫苗相比，含 Toll 样受体 9 激动剂佐剂（HBsAg-1018）的乙型肝炎疫苗的免疫原性和安全性。
Vaccine. 2013 Nov 4;31(46):5300-5. doi: 10.1016/j.vaccine.2013.05.068. Epub 2013 May 30.
7
Long-term response rates of successful hepatitis B vaccination in HIV-infected patients.成功的乙型肝炎疫苗接种在 HIV 感染患者中的长期应答率。
Vaccine. 2013 Feb 4;31(7):1040-4. doi: 10.1016/j.vaccine.2012.12.047. Epub 2012 Dec 28.
8
Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.在 18-55 岁健康成年人中，比较两种剂量的研究用乙型肝炎病毒表面抗原与免疫刺激性硫代磷酸寡脱氧核苷酸联合使用，以及三种剂量的已上市乙型肝炎疫苗的安全性和免疫原性。
Vaccine. 2012 Mar 28;30(15):2556-63. doi: 10.1016/j.vaccine.2012.01.087. Epub 2012 Feb 9.
9
Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220.使用粒细胞-巨噬细胞集落刺激因子（GM-CSF）作为疫苗佐剂的 HIV 感染者对乙型肝炎疫苗的免疫反应：ACTG 研究 5220。
Vaccine. 2010 Aug 2;28(34):5597-604. doi: 10.1016/j.vaccine.2010.06.030. Epub 2010 Jun 23.